Generics make up 90 percent of the American drug supply, notes Katherine Eban, author of the forthcoming Bottle of Lies: The Inside Story of the Generic Drug Boom. Eban argues, however, that foreign inspections reveal dangerous compromises behind the production of generic drugs—and FDA’s limits as a global regulatory agency.
Want to dig deeper on generic drugs and pharmacovigilance?
-
Webinar
Liang Zhao, Director for the Division of Quantitative Methods and Modeling in FDA’s Office of Generic Drugs, on novel ways FDA is developing and demonstrating generic drug safety.
Download Now -
Article
How the National Drug Administration of China will significantly improve the quality of drug safety and surveillance in China.
Read Now -
Video and Podcast
Howard Chazin, Director, Clinical Safety Surveillance Staff, Office of Generic Drugs, CDER FDA, on how FDA interprets generic drug regulation and safety reporting requirements to ensure generic drug safety, and why the American public should have confidence in generics.
Listen Now
Watch Now -
Article
Jodi B. Segal on Determinants of Generic Drug Substitution in the United States, from Therapeutic Innovation & Regulatory Science
Read Now
Member-only content
-
Podcast
Maryll Toufanian, Acting Director, US FDA Office of Generic Drug Policy, on the US FDA’s Drug Competition Action Plan and why US consumers can feel safe taking generic drugs.
Listen Now
Want to learn more?
Our upcoming DIA 2019 Global Annual Meeting features numerous sessions and perspectives on generic drugs, or take our online course on Postmarketing Safety Management.
Related Perspectives
View all Deep Dives-
Op-Ed
From The New York Times: Americans Need Generic Drugs. But Can They Trust Them?
Read Now -
Article
From Harvard Health Publishing: Do Generic Drugs Compromise on Quality?
Read Now -
Book Review and Interview
From NPR: The Dark Side Of The Generic Drug Boom – Bottle of Lies book review and interview with the author
Listen Now
Read Now